ADLARITY® (donepezil transdermal system).

NOW APPROVED

Available early fall 2022

Introducing ADLARITY®, the first and only once-weekly donepezil transdermal system—featuring Corplex™ technology.1,2

ERROR 404

Sorry, we can't find the page you are looking for.

ERROR 500

The server encountered a problem and we are unable to complete your request. Please try again later.

Sign up to receive the latest news and information about ADLARITY

*All fields are required

Please correct the errors before submitting this form.

By clicking the Submit button, you are confirming that you are aged 18 years or older and that you agree to receive information from Corium, Inc. You will be able to revoke this permission at any time by opting out. Read the full Terms of Use and Privacy Policy.

References: 1. ADLARITY. Prescribing information. Corium Inc; 2022. 2. Singh P, Lee ES, Jain AK, inventors; Corium International, Inc., assignee. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery. U.S. patent 10,016,372. July 10, 2018.